*Safety and efficacy have been established in pediatric patients. *Use is supported by a single-arm trial in pediatric patients with relapsed or refractory B-cell precursor ALL. *This study included 70 pediatric patients 1 month to less than 18 years. *Adverse reactions that were observed more frequently in the pediatric population compared to the adult population were anemia (41% vs 18%), thrombocytopenia (21% vs.11%), vomiting (24% vs. 13%), pyrexia (80% vs. 62%), and hypertension (26% vs. 8%). In pediatric patients less than 2 years old (infants), the incidence of neurologic toxicities was not significantly different than for the other age groups, but its manifestations were different; the only event terms reported were agitation, headache, insomnia, somnolence, and irritability. Infants also had an increased incidence of hypokalemia (50%) compared to other pediatric age cohorts (15-20%) or adults (23%). *Information on dosing, adverse reactions, and clinical trial.
|